Angioplasty in sirolimus – eluting stent restenosis is safe and effective beyond the change of drug.

Original title: Sirolimius-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stents restenosis: Results from the ISAR-DESIRE 2 trial. Reference: Sebastian Kufner, et al. Cardiovascular Revascularization Medicine 2014, 15:69-75.

 

DES restenosis has always generated a challenge and a puzzle when defining the strategy of revascularization by angioplasty: A quite used concept was to switch to another drug. While this has not been tested in major randomized studies, is often a common practice.

In this randomized study, symptomatic patients experiencing angina or myocardial ischemia and restenosis ≥ 50 % of sirolimus – eluting stents (Cypher SES) were included. Patients were randomized to angioplasty with a new sirolimus – eluting stent (Cypher SES group) or switch to a paclitaxel – eluting stent (Taxus PES group). The study primary endpoint was in-stent late lumen loss, and the secondary the binary restenosis, both at 12 months. Of the 450 patients registered, 162 (36 %) were diabetics of whom 86 received SES and 76 PES. Among the 288 non-diabetics, 139 received SES and 149 PES. There were no differences in clinical, angiographic or morphological restenosis characteristics within different groups, being the focal restenosis the most common type. After 12 months no difference in the primary endpoint were observed (in-stent late lumen loss) both among diabetics (SES 0.38±0.59 mm versus PES 0.37±0.59mm; p=0.97) as in non-diabetics (SES 0.41±0.67mm versus PES 0.38±0.60mm; p=0.89). The secondary end point (binary restenosis) was not different between groups beyond being diabetic or not (SES 19% versus PES 26%; p=0.32 in the diabetic group and SES 19.9 % versus PES 17.8 %, P = 0.36 in non-diabetics).

The most frequent morphological pattern of restenosis was the focal again. There was no difference in the rate of target lesion revascularization between groups (SES 16.3% versus PES15.8% in diabetics and SES 14.1% versus PES 12.1% in non-diabetic). Safety endpoints such as death, myocardial infarction and stent thrombosis considered separately or compound thereof also showed similar results.

Conclusion:

In the restenosis case caused by SES, the treatment with a new SES implant or rotate a PES, was associated with comparable efficacy in both diabetic and nondiabetic patients. 

Editorial comment

This randomized and controlled trial shows us that in first generation SES restenosis, performing an angioplasty with another SES of the same generation with the same or different drug is feasible in both, diabetic and nondiabetic patients getting good results and maintaining safety and effectiveness of the procedure. While this is about first generation of DES, would be good to test them with the second generation. 

Courtesy of Carlos Fava, MD
Interventional cardiologist
Fundacion Favaloro – Buenos Aires

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | FLAVOUR II: Angiography-Derived FFR-Guided vs. IVUS-Guided PCI

Physiological assessment is effective when it comes to decision-making for percutaneous coronary intervention (PCI). However, despite the available evidence, its use remains limited. AngioFFR...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...